Pregnancy Biomarkers Reveal Long-Term Cardiovascular Risk in Women

Why It Matters

Identifying CVD risk during pregnancy could shift preventive care earlier, reducing future morbidity and health‑care costs for women.

Key Takeaways

• Third‑trimester hs‑cTnI predicts future cardiovascular events
• Week‑29 sFlt‑1 adds 0.16 ΔAUC to age model
• Predictive value holds in women without pregnancy hypertension
• Study limited by only 28 CVD events
• Findings may not generalize beyond Northern Europe

Pulse Analysis

Cardiovascular disease remains the leading cause of death among women, yet traditional risk assessments often miss sex‑specific predictors. Pregnancy, a period of heightened hemodynamic stress, offers a unique physiological window to uncover latent vascular vulnerability. Biomarkers such as hs‑cTnI, a marker of myocardial injury, and sFlt‑1, an anti‑angiogenic factor, rise naturally in late gestation, reflecting the heart’s response to the increased circulatory load. By measuring these markers at week 29, clinicians can capture a snapshot of cardiovascular strain that may herald future disease.

The Danish Odense Child Cohort provides robust registry data that linked third‑trimester biomarker levels to subsequent CVD events over nearly 12 years. The study demonstrated that week‑29 sFlt‑1, when combined with maternal age, improved risk discrimination (ΔAUC 0.16) beyond a model using age, systolic blood pressure, and non‑HDL cholesterol. Importantly, the predictive signal persisted among women without prior hypertension or hypertensive disorders of pregnancy, indicating that these biomarkers could identify risk even in ostensibly low‑risk pregnancies. This evidence challenges the reliance on traditional obstetric complications alone for long‑term cardiovascular screening.

Despite promising results, the analysis is constrained by only 28 cardiovascular events, limiting statistical power, and by its focus on a largely Northern European population, raising questions about broader applicability. Missing first‑trimester data for NT‑proBNP and hs‑cTnI further narrows the temporal insight. Nonetheless, the findings spark a compelling argument for integrating pregnancy‑derived biomarkers into women’s lifelong cardiovascular risk algorithms, pending validation in larger, more diverse cohorts. If confirmed, such an approach could enable earlier lifestyle interventions, targeted monitoring, and ultimately reduce the gender gap in cardiovascular outcomes.